

Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020

<https://marketpublishers.com/r/A919692EEDECEN.html>

Date: November 2020

Pages: 40

Price: US\$ 1,500.00 (Single User License)

ID: A919692EEDECEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Angioimmunoblastic T-cell lymphoma Understanding

Angioimmunoblastic T-cell lymphoma: Overview

Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell lymphoma arising from follicular helper T cells of the germinal center. AITL is characterized by the transformation of a T-cell into a malignant cell. It is a systemic disease that is present with generalized lymphadenopathy, hepatosplenomegaly, constitutional symptoms, skin rash, anemia, and polyclonal hypergammaglobulinemia. The Abnormal, uncontrolled growth and multiplication (proliferation) of malignant T-cells may lead to enlargement of a specific lymph node region or regions.

Symptoms

The symptoms of Angioimmunoblastic T-cell lymphoma include:

high fever

night sweats

skin rash

enlargement of a specific lymph node region or regions

autoimmune disorders such as autoimmune hemolytic anemia and immune thrombocytopenia

Diagnosis

Diagnosis of Angioimmunoblastic T-cell lymphoma (AITL) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a biopsy of an affected lymph node or other affected areas such as the skin or bone marrow. A series of other tests may be done to determine the extent, or stage, of the disease such as blood tests, specialized imaging tests and bone marrow examination. Specialized imaging techniques may include magnetic resonance imaging (MRI), computed tomography (CT) scanning, and positron emission tomography (PET scan).

Treatment

Treatment of Angioimmunoblastic T-cell lymphoma is based on the assessment of the extent or “stage” of the disease progression, tumor size, presence or absence of certain symptoms, an individual’s age and general health. It will help in characterizing the potential disease course and appropriate treatment approaches. A combination of chemotherapy and immunotherapy (chemoimmunotherapy) have been used. Corticosteroids, such as prednisone, are used to treat the symptoms of AITL that result from dysfunction of the immune system. Investigational therapies includes low dose methotexate with corticosteroids, thalidomide, lenalidomide, bevacizumab, alemtuzumab, fludarabine and 2-chlordeoxyadenosine. The use of interferon alfa in association with or following chemotherapy is also under evaluation.

Angioimmunoblastic T-cell lymphoma Emerging Drugs Chapters

This segment of the Angioimmunoblastic T-cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angioimmunoblastic T-cell lymphoma Emerging Drugs

Tipifarnib: Kura Oncology

Tipifarnib, is a potent and highly selective inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development. The therapy was in-licensed from Janssen in December 2014. In March 2020 Kura Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL).

AUTO4: Autolus

AUTO4 is a programmed T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1, a novel and differentiated treatment approach. AUTO4 is designed to selectively kill cancerous T cells in a manner will preserve a portion of the patient's normal, healthy T cells to maintain immunity. AUTO4 is currently in a Phase I study in TRBC1-positive peripheral T cell lymphoma.

Further product details are provided in the report

Angioimmunoblastic T-cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Angioimmunoblastic T-cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Angioimmunoblastic T-cell lymphoma

There are approx. 10+ key companies which are developing the therapies for Angioimmunoblastic T-cell lymphoma. The companies which have their Angioimmunoblastic T-cell lymphoma drug candidates in the most advanced stage, i.e. phase II include, Kura Oncology.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Angioimmunoblastic T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angioimmunoblastic T-cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioimmunoblastic T-cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioimmunoblastic T-cell lymphoma drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Angioimmunoblastic T-cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma Report Insights

Angioimmunoblastic T-cell lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Angioimmunoblastic T-cell lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Angioimmunoblastic T-cell lymphoma drugs?

How many Angioimmunoblastic T-cell lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angioimmunoblastic T-cell lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angioimmunoblastic T-cell lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Angioimmunoblastic T-cell lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Kura Oncology

Bristol-Myers Squibb

Celgene

Pfizer

Autolus

BeiGene

Amgen

CerRx

PersonGen Biotherapeutics

Takeda

Celgene

Arno Therapeutics

Key Products

Tipifarnib

Dasatinib

Enasidenib

Azacitidine

AUTO4

Tislelizumab

Carfilzomib

Fenretinide intravenous

CD7-CAR-T cells

MLN8237

Bortezomib

Lenalidomide

AR-42

Contents

Introduction

Executive Summary

Angioimmunoblastic T-cell lymphoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Angioimmunoblastic T-cell lymphoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Angioimmunoblastic T-cell lymphoma companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Angioimmunoblastic T-cell lymphoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Tipifarnib: Kura Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

Dasatinib: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Angioimmunoblastic T-cell lymphoma Key Companies

Angioimmunoblastic T-cell lymphoma Key Products

Angioimmunoblastic T-cell lymphoma- Unmet Needs

Angioimmunoblastic T-cell lymphoma- Market Drivers and Barriers

Angioimmunoblastic T-cell lymphoma- Future Perspectives and Conclusion

Angioimmunoblastic T-cell lymphoma Analyst Views

Angioimmunoblastic T-cell lymphoma Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Angioimmunoblastic T-cell lymphoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Angioimmunoblastic T-cell lymphoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/A919692EEDECEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A919692EEDECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970